AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

Buobe IA context · why it matters

AstraZeneca's shares fell 8.9% over merger talks — Investors are skeptical about potential deals.
Sir Pascal Soriot has a successful track record with previous acquisitions — This suggests sticking to current strategy might be wise. AstraZeneca should focus on its existing growth opportunities rather than pursuing an expensive mega-merger.

Published by

on •1 min read

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling• AstraZeneca shares fall 8.9% over merger talks with US cancer drug firmSir Pascal Soriot, chief executive of AstraZeneca, starts with huge credit in the bank, obviously.

merger pharmaceuticals stock market

Learn more